Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
27.05
-0.14 (-0.51%)
At close: Aug 14, 2026, 4:00 PM EDT
26.85
-0.20 (-0.74%)
After-hours: Aug 14, 2026, 7:59 PM EDT
Nurix Therapeutics Revenue
Nurix Therapeutics had revenue of $9.04M in the quarter ending May 31, 2026, a decrease of -79.47%. This brings the company's revenue in the last twelve months to $36.77M, down -58.40% year-over-year. In the fiscal year ending November 30, 2025, Nurix Therapeutics had annual revenue of $83.98M with 53.95% growth.
Revenue (ttm)
$36.77M
Revenue Growth
-58.40%
P/S Ratio
76.36
Revenue / Employee
$115,981
Employees
317
Market Cap
2.81B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Nov 30, 2025 | 83.98M | 29.43M | 53.95% |
| Nov 30, 2024 | 54.55M | -22.44M | -29.15% |
| Nov 30, 2023 | 76.99M | 38.36M | 99.31% |
| Nov 30, 2022 | 38.63M | 8.88M | 29.84% |
| Nov 30, 2021 | 29.75M | 11.93M | 66.95% |
| Nov 30, 2020 | 17.82M | -13.30M | -42.73% |
| Nov 30, 2019 | 31.12M | -6.33M | -16.91% |
| Nov 30, 2018 | 37.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 717.00M |
| Tarsus Pharmaceuticals | 606.33M |
| Zai Lab | 449.61M |
| Iovance Biotherapeutics | 324.97M |
| Beam Therapeutics | 156.04M |
| Nektar Therapeutics | 55.63M |
| Alumis | 8.40M |
| AtaiBeckley | 4.47M |
NRIX News
- 11 days ago - Nurix earns $10M milestone from Sanofi on STAT6 degrader Phase 1 start - TheFly
- 11 days ago - Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader - GlobeNewsWire
- 11 days ago - Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - GlobeNewsWire
- 18 days ago - Nurix Therapeutics price target raised to $38 from $36 at Morgan Stanley - TheFly
- 24 days ago - Nurix Therapeutics price target raised to $31 from $23 at UBS - TheFly
- 24 days ago - Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics price target raised to $34 from $30 at Mizuho - TheFly
- 5 weeks ago - Nurix Therapeutics price target raised to $34 from $32 at Truist - TheFly